Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin

Good momentum in commercial CDMO business

Merck receives positive EU CHMP opinion for pembrolizumab plus Trastuzumab and Chemotherapy as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction

If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU

Glenmark Life Sciences reports robust 25% EBITDA growth in Q1FY24

The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.

SEBI approves Piramal Pharma’s Rs 1,050-crore rights issue

Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders

Lonza launches new cell culture media system TheraPRO

The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production

PredOmix, Core Diagnostics partner to launch OncoVeryx-F

OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection

JeNaCell launches wound dressing epicite balance for chronic wounds

Moist wound dressing for chronic wound treatment now available in Germany

Evonik and Heraeus cooperate to expand the range of services for highly potent API

Evonik specializes in mid- to large-scale, later clinical phase HPAPIs

Dupixent is now approved in India for the treatment of adults with moderate-to-severe atopic dermatitis

Lupin receives approval from USFDA for Chlorpromazine Hydrochloride Tablets USP

Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.